Zealand Pharma A/S
CSE:ZEAL
Intrinsic Value
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. [ Read More ]
The intrinsic value of one
ZEAL
stock under the Base Case scenario is
305.63
DKK.
Compared to the current market price of 657.5 DKK,
Zealand Pharma A/S
is
Overvalued by 54%.
Zealand Pharma A/S's market capitalization is 38.4B DKK.
ZEAL stock price is 657.5 DKK.
ZEAL stock (305.63 DKK) is 54% less than its price (657.5 DKK).
ZEAL stock (267.27 DKK) is 59% less than its price (657.5 DKK). Open Relative Valuation
ZEAL has upside potential of 22% compared to the average analyst price target.
Open Wall St Estimates
ZEAL's ROE (Return on Equity) has increased in the last 3 years from -63% to -58%, and is approaching profitability.
ZEAL's Revenue has been growing by an exceptional 21% per year for the last 3 years.
ZEAL's Revenue has grown by an exceptional 230% over the past 12 months.
ZEAL's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -237% to -346%, and is approaching profitability.
ZEAL has negative Operating Income for the last twelve months.
ZEAL has negative Net Income for the last twelve months.
ZEAL's ROE (Return on Equity) for the past 12 months is negative and is equal to -58%.
ZEAL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -346%.
ZEAL has positive Gross Profit for the last twelve months.
ZEAL's Revenue is forecast to grow at a rate of 79% per year over the next 3 years.
ZEAL has negative Free Cash Flow for the last twelve months.
ZEAL's D/E (Debt to Equity) is very low and is equal to 0.06.
ZEAL has negative three-year average ROE (Return on Equity): -104%. The company is not efficient at transforming stockholders' equity into net income.
ZEAL has negative three-year average ROIC (Return on Invested Capital): -217%. The company is not efficient at using invested capital to generate operating income.
ZEAL's short-term assets (2B DKK) exceed its short-term liabilties (285m DKK).
ZEAL's long-term assets (2B DKK) exceed its long-term liabilties (387m DKK).
ZEAL has negative Net Debt. This means that the company has more cash and short-term investments (2B DKK) than debt (103m DKK).
ZEAL's Altman Z-Score is very high and is equal to 29.46.
ZEAL doesn't generate enough operating income (-561m DKK) to safely cover interest payments on its debt (25m DKK).
Valuation Backtest
Zealand Pharma A/S
Run backtest to discover the historical profit from buying and selling
ZEAL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Zealand Pharma A/S
Balance Sheet Decomposition
Zealand Pharma A/S
| Current Assets | 1.8B |
| Cash & Short-Term Investments | 1.6B |
| Receivables | 110.8m |
| Other Current Assets | 35.9m |
| Non-Current Assets | 200.2m |
| Long-Term Investments | 21.4m |
| PP&E | 149.9m |
| Intangibles | 12.3m |
| Other Non-Current Assets | 16.7m |
| Current Liabilities | 284.6m |
| Accounts Payable | 206.1m |
| Accrued Liabilities | 51.7m |
| Other Current Liabilities | 26.7m |
| Non-Current Liabilities | 102.6m |
| Long-Term Debt | 102.6m |
Earnings Waterfall
Zealand Pharma A/S
|
Revenue
|
342.8m
DKK
|
|
Cost of Revenue
|
-19.2m
DKK
|
|
Gross Profit
|
323.6m
DKK
|
|
Operating Expenses
|
-884.9m
DKK
|
|
Operating Income
|
-561.2m
DKK
|
|
Other Expenses
|
-142.5m
DKK
|
|
Net Income
|
-703.7m
DKK
|
Free Cash Flow Analysis
Zealand Pharma A/S
ZEAL Profitability Score
Profitability Due Diligence
Zealand Pharma A/S's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Zealand Pharma A/S's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ZEAL Solvency Score
Solvency Due Diligence
Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZEAL Price Targets Summary
Zealand Pharma A/S
According to Wall Street analysts, the average 1-year price target for
ZEAL
is 805.04 DKK
with a low forecast of 606 DKK and a high forecast of 882 DKK.
Shareholder Return
ZEAL Price
Zealand Pharma A/S
| Average Annual Return | 17.32% |
| Standard Deviation of Annual Returns | 45.21% |
| Max Drawdown | -76% |
| Market Capitalization | 38.4B DKK |
| Shares Outstanding | 62 270 400 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Zealand Pharma A/S
Country
Industry
Market Cap
Dividend Yield
Description
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. The firm's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
Contact
IPO
Employees
Officers
The intrinsic value of one
ZEAL
stock under the Base Case scenario is
305.63
DKK.
Compared to the current market price of 657.5 DKK,
Zealand Pharma A/S
is
Overvalued by 54%.
You don't have any saved screeners yet
